Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
NCT ID: NCT00405873
Last Updated: 2013-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
73 participants
INTERVENTIONAL
2007-03-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary endpoint is best overall response rate within 20 weeks after registration
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
NCT03113604
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
NCT05653427
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
NCT00427973
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04487067
Adjuvant Therapy With Anlotinib for HCC
NCT04947371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The best overall response rate is the best response recorded from the start of treatment until disease progression / recurrence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMT2003
AMT2003
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMT2003
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one measurable lesion
* Advanced disease refractory to standard therapy or for which no standard therapy exists
* Life expectancy of at least 3 months
Exclusion Criteria
* Body weight below 45 kg
* Female patients who are pregnant or breast feeding or adults of reproductive potential not employing effective method of birth control
* Confirmed diagnosis of HIV
* Insulin dependent diabetes mellitus / abnormal glucose tolerance test (GTT) / latent diabetes mellitus type I or II
* Chemotherapy or radiotherapy less than 4 weeks prior to entry
* Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)
* Participation in a clinical trial less than 30 days prior to entry into study
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Auron Healthcare GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hubert Blum, Prof. Dr. med. Dr. h. c.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Freiburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Freiburg, Dept. of Internal Medicine II
Freiburg im Breisgau, Baaden-Wuerttemberg, Germany
Clinic SanaFontis
Freiburg im Breisgau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Now legally responsible for study
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LC004AURON2005
Identifier Type: -
Identifier Source: secondary_id
AMT/P2GI/001 Part I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.